Page last updated: 2024-12-08
bharangin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
bharangin: inhibits the activity of penicillinase enzyme in E coli [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 194464 |
| CHEMBL ID | 1807756 |
| MeSH ID | M0166566 |
Synonyms (8)
| Synonym |
|---|
| bharangin |
| 72711-84-3 |
| CHEMBL1807756 |
| benzo(5,6)cyclohepta(1,2-b)pyran-2,9-dione, 3,4,11,11a-tetrahydro-10-hydroxy-4,4,11a-trimethyl-8-(1-methylethyl)-, (s)- |
| DTXSID00993529 |
| 10-hydroxy-4,4,11a-trimethyl-8-(propan-2-yl)-3,4,11,11a-tetrahydrobenzo[5,6]cyclohepta[1,2-b]pyran-2,9-dione |
| (3s)-15-hydroxy-3,7,7-trimethyl-13-propan-2-yl-4-oxatricyclo[9.4.0.03,8]pentadeca-1(15),8,10,12-tetraene-5,14-dione |
| AKOS040747960 |
Research Excerpts
Overview
Bharangin is a diterpenoid quinonemethide. It has demonstrated therapeutic potential against leukemia, lymphoma, and multiple myeloma cells.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bharangin is a diterpenoid quinonemethide that has demonstrated therapeutic potential against leukemia, lymphoma, and multiple myeloma cells." | ( Anti-cancer activities of Bharangin against breast cancer: Evidence for the role of NF-κB and lncRNAs. Awasthee, N; Gupta, SC; Nair, MS; Rai, V; Sajin Francis, K; Verma, SS, 2018) | 1.5 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID608688 | Cytotoxicity against human A549 cells after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15 | Cytotoxic diterpenoid quinonemethides from the roots of Pygmacopremna herbacea. |
| AID608689 | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15 | Cytotoxic diterpenoid quinonemethides from the roots of Pygmacopremna herbacea. |
| AID608691 | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15 | Cytotoxic diterpenoid quinonemethides from the roots of Pygmacopremna herbacea. |
| AID608687 | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15 | Cytotoxic diterpenoid quinonemethides from the roots of Pygmacopremna herbacea. |
| AID608690 | Cytotoxicity against human PC3 cells after 48 hrs by MTT assay | 2011 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15 | Cytotoxic diterpenoid quinonemethides from the roots of Pygmacopremna herbacea. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.52) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||